Mriglobal

Mriglobal, doing business as Midwest Research Institute, is a Kansas City, Missouri-based 501(c)(3) nonprofit research organization that delivers clinical-grade pharmaceutical manufacturing, preclinical testing, diagnostic services, and biodefense research and development to federal agencies as a prime contractor (99% of awards) across health, defense, and homeland security missions.

Mriglobal operates as a large, unrestricted prime contractor—no small business set-asides apply to its footprint. The organization reports over $110 million in annual research revenue and maintains sophisticated laboratory facilities across multiple locations, including headquarters at 425 Dr. Martin Luther King Jr. Boulevard in Kansas City (225,000 square feet with 60,000 square feet of laboratory space), a North Kansas City biorepository facility (87,000 square feet), and operational sites in Potomac, Maryland; Frederick, Maryland; Edison, New Jersey; and other subordinate locations. Recent prime work centers on pharmaceutical manufacturing and regulatory support for infectious disease countermeasures, diagnostic product development, chemical and biological threat detection, and biocontainment platform modernization. Representative awards include a $1.57 million NIAID delivery order (May 2026) for FDA 510(k) enabling studies on ciprofloxacin-resistance diagnostics, a $3.46 million National Cancer Institute order (September 2025) for clinical-grade Epstein-Barr virus vaccine manufacture, a $13.6 million EPA environmental response contract (January 2025) for Portable High Throughput Integrated Laboratory Identification Systems modernization with Craftsmen Industries and Bison Group USA as named subcontractors, and a $28.9 million Department of Defense contract (August 2022) for Chemical, Biological, Radiological, and Nuclear laboratory services supporting the Pentagon Force Protection Agency with Quicksilver Analytics as a Service-Disabled Veteran-Owned Small Business subcontractor.

Customer concentration clusters heavily in health and biodefense domains. Across five customer agencies accounting for approximately 47% of awards by count, the National Institute of Allergy and Infectious Diseases dominates both volume and dollars (16 awards, $655.8 million potential value), followed by the Office of the Assistant Secretary for Preparedness and Response (17 awards, $515.3 million), the National Cancer Institute (26 awards, $271.8 million), the Centers for Disease Control and Prevention (30 awards, $163.7 million), and the National Center for Advancing Translational Sciences (8 awards, $125.2 million). A second tier includes the Environmental Protection Agency (228 awards by count but only $17 thousand potential value—indicating small environmental consulting or technical representative work), the Department of the Army, the Air Force Space Command, and the Air Force. These health and HHS agencies account for the overwhelming majority of Mriglobal's dollar exposure; of the five customers ranking highest by potential value, all are HHS components, anchoring approximately $1.73 billion of the vendor's total $65.79 billion combined potential value.

Mriglobal holds multiple large indefinite delivery vehicles anchoring its federal footprint. The most significant is a $545.5 million single-award NIAID contract for Comprehensive and Rapid Response to NIAID Research Programs (awarded September 2021, through August 2028), which supports clinical trials, manufacturing and controls, nonclinical animal studies, analytics, biostatistics, specimen storage, and regulatory services across NIAID's divisions. Other major IDVs include a $146.3 million NIAID single-award contract for preclinical evaluation of infectious disease countermeasures (through August 2024, now superseded), a $148 million CDC multiple-award diagnostic testing IDIQ (September 2025–2030), a $100 million ASPR single-award contract for biological animal models and medical countermeasures (through September 2027), a $49.7 million NCATS single-award contract for chemistry, manufacturing, and controls services (through May 2031), a $49.99 million NCATS multiple-award contract for analysis and synthesis of bulk drugs and pharmaceutical formulations (through April 2028), a $49.99 million NCI single-award contract for centralized chemopreventive agent repository and chemistry support (through June 2028), a $49.99 million NINDS multiple-award Drug Manufacturing and Formulation Program contract (awarded May 2026, through May 2036), and a government-wide seat on the OASIS+ Unrestricted IDIQ (awarded December 2024, through December 2029). The top five parent vehicles by task-order volume include an IDC carrying 133 task orders (uncategorized in the source), the Air Force Space Command F0865003D0004 IDIQ (64 task orders, $9.5 million potential value), and three Army, Navy, and Air Force-managed IDVs with 15–18 task orders each.

Activity has been volatile: 13 awards in 2022, 20 in 2023, 23 in 2024, dropping to 4 in 2025 and 5 through early June 2026. Over the next twenty-four months, eighteen awards with combined potential value of $321.9 million reach ultimate completion, creating significant recompete exposure concentrated in the health and biodefense portfolio. The $146.3 million NIAID preclinical infectious disease countermeasures contract is included in this recompete cliff and faces expiration or renegotiation.

Service Contract Inventory data (reporting threshold $150,000, covering federal service contracts only) shows SCI-reported invoicing of $53.8 million across three fiscal years (FY2022–FY2024): $15 million in FY2022 across 35.6 full-time equivalents, $17.2 million in FY2023 across 39.4 FTEs, and $21.6 million in FY2024 across 47.1 FTEs. SCI-reported FTE growth has accelerated year over year. On federal services contracts captured in SCI, government-paid median hourly rates run around $257.91/hr, with senior labor pricing reaching through $670.89/hr and entry-level labor at roughly $111.64/hr. Across SCI-reportable prime contracts, Mriglobal self-performs approximately 98% of contractor hours, with an average subcontractor share of 2%; the vendor names twelve total subcontractors across prime service contracts, indicating a primarily integrated delivery model rather than a heavy-sub-reliance posture.

Mriglobal subcontracts to larger primes on a limited basis—recent sub work includes technical support to Draper Laboratories on a DARPA research program (May 2024), BioFire Defense work on next-generation pandemic vaccine testing and assay reproducibility (January and May 2024), Mitchell Group support on NIAID vaccine safety toxicology (January 2024), and National Strategic Research Institute subcontracting on chemical, biological, radiological, and nuclear defense research and development (July 2023). Federal grant activity is minimal; the source lists three grants as prime recipient, all congressionally directed spending awards for facility and capability expansion at the Kansas City headquarters (funded by HUD's Healthcare Systems Bureau in 2022 and 2023, and the HUD Assistant Secretary for Community Planning and Development in 2024) with combined completion dates through 2032. Sub-grant work includes proficiency testing panel preparation for the Association of Public Health Laboratories (August 2024) and vesicant injury therapy research under the University of Colorado (February 2024).

The vendor's portfolio is heavily concentrated in full-and-open federal research and development work, with no set-aside awards, reflecting Mriglobal's scale and established position as a sole-source or competitive prime across health, biodefense, and environmental markets. Recent capability expansion and facility investment signal intent to sustain and grow its leadership position in pharmaceutical manufacturing, diagnostics, and infectious disease countermeasure development for federal agencies.